Skip to main content
. 2012 Mar 30;13(5):407–414. doi: 10.1007/s10194-012-0440-y

Table 3.

Adverse events in both treatment groups

Rizatriptan 10 mg (n = 41 patients) Placebo (n = 39 patients)
Any 5 (12 %) 4 (10 %)
Nausea 1 (2 %) 2 (5 %)
Somnolence 2 (5 %) 0 (0 %)
Dizziness 2 (5 %) 0 (0 %)
Fatigue 0 (0 %) 1 (2.5 %)
Tachycardia 0 (0 %) 1 (2.5 %)